Professor Nicholas Latimer

All publications

Journal articles

• Latimer N (2024) A comparison of the effectiveness of different treatment regimens for pancreatic cancer using English cancer registry data. SCHARR HEDS Discussion Paper(24.05). View this article in WRRO
• Bullement A, Edmondson-Jones M, Guyot P, Welton NJ, Baio G, Stevenson M & Latimer NR (2024) MPES-R: multi-parameter evidence synthesis in R for survival extrapolation—a tutorial. PharmacoEconomics. View this article in WRRO
• Taylor K, Latimer NR, Douglas T, Hatswell AJ, Ho S, Okorogheye G, Borril J, Chen C, Kim I & Bertwistle D (2024) Treatment effect waning in immuno-oncology health technology assessments: a review of assumptions and supporting evidence with proposals to guide modelling. PharmacoEconomics. View this article in WRRO
• Bullement A, Edmondson-Jones M & Latimer N (2024) Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach. BMC Cancer, 24(1), 879.
• Jennings AC, Rutherford MJ, Latimer NR, Sweeting MJ & Lambert PC (2023) Perils of randomised controlled trial survival extrapolation assuming treatment effect waning: why the distinction between marginal and conditional estimates matters. Value in Health, S1098-3015(23)06241.
• Bell Gorrod H, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) MSR9 Adjusting for Switches to Multiple Treatments in Randomised Controlled Trials: A Comparison of Inverse Probability Weighting and Two-Stage Estimation Methods. Value in Health, 26(12), S394-S394.
• Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) P51 Testing a Survival Extrapolation Algorithm for Cancer Immunotherapies: Pass or Fail?. Value in Health, 26(12), S13-S13.
• Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) MSR156 Evaluating Bias Associated With Inadequate Variable Selection When Using Inverse Probability of Censoring Weights to Adjust for Treatment Switches in Clinical Trials. Value in Health, 26(12), S423-S424.
• Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) MSR147 Accounting for Study Heterogeneity When Modelling the Multi-State Natural History of Rare Diseases. Value in Health, 26(12), S421-S422.
• Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) HTA237 Treatment Effect Waning in Immuno-Oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence. Value in Health, 26(12), S365-S365.
• Broomfield J, Abrams K, Latimer N, Guglieri M, Rutherford M & Crowther M (2023) Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink. Brain and Behavior, e3331.
• Turner AJ, Sammon C, Latimer N, Adamson B, Beal B, Subbiah V, Abrams KR & Ray J (2023) Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments. PharmacoEconomics, 1-12.
• Lee S, Lambert PC, Sweeting MJ, Latimer NR & Rutherford MJ (2023) Evaluation of flexible parametric relative survival approaches for enforcing long-term constraints when extrapolating all-cause survival. Value in Health.
• Bullement A, Stevenson MD, Baio G, Shields GE & Latimer NR (2023) A systematic review of methods to incorporate external evidence into trial-based survival extrapolations for health technology assessment. Medical Decision Making, 43(5), 610-620.
• Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) TREATMENT EFFECT WANING IN IMMUNO-ONCOLOGY HEALTH TECHNOLOGY ASSESSMENTS: A REVIEW OF ASSUMPTIONS AND SUPPORTING EVIDENCE. VALUE IN HEALTH, 26(12), S365-S365.
• Bullement A, Critchlow S, Stevenson MD, Baio G & Latimer N (2022) A REVIEW OF EXTERNAL EVIDENCE USED TO SUPPORT SURVIVAL EXTRAPOLATION IN ASSESSMENTS OF CANCER DRUGS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). VALUE IN HEALTH, 25(12), S340-S340.
• Morga A, Latimer NR, Scott M, Hawkins N, Schlichting M & Wang J (2022) Is intention to treat still the gold standard or should health technology assessment agencies embrace a broader estimands framework? : Insights and perspectives from the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum. Value in Health.
• Nimmo A, Latimer N, Oniscu GC, Ravanan R, Taylor DM & Fotheringham J (2022) Propensity score and instrumental variable techniques in observational transplantation studies: an overview and worked example relating to pre-transplant cardiac screening. Transplant International, 35. View this article in WRRO
• Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) An app with brief behavioural support to promote physical activity after a cancer diagnosis (APPROACH) : study protocol for a pilot randomised controlled trial. Pilot and Feasibility Studies, 8(1), 74-74.
• Gomes M, Latimer N, Soares M, Dias S, Baio G, Freemantle N, Dawoud D, Wailoo A & Grieve R (2022) Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real-world data : opportunities and challenges. PharmacoEconomics.
• Latimer NR & Adler AI (2022) Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. BMJ Medicine, 1.
• Adler AI & Latimer NR (2021) Adjusting for nonadherence or stopping treatments in randomized clinical trials. JAMA : the Journal of the American Medical Association, 325(20), 2110-2111.
• Latimer NR, Towse A & Henshall C (2021) Not cost-effective at zero price : valuing and paying for combination therapies in cancer. Expert Review of Pharmacoeconomics & Outcomes Research.
• Srivastava T, Latimer NR & Tappenden P (2021) Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals. PharmacoEconomics.
• Fotheringham J, Latimer N, Froissart M, Kronenberg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler DC (2020) Survival on four-times-per-week compared with three times a week haemodialysis in high ultrafiltration patients : an observational study. Clinical Kidney Journal.
• Woods BS, Sideris E, Palmer S, Latimer N & Soares M (2020) Partitioned survival and state transition models for healthcare decision making in oncology : where are we now?. Value in Health.
• Palmer R, Dimairo M, Latimer N, Cross E, Brady M, Enderby P, Bowen A, Julious S, Harrison M, Alshreef A , Bradley E et al (2020) Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia : the Big CACTUS three-arm RCT. Health Technology Assessment, 24(19), 1-176. View this article in WRRO
• Latimer N, White IR, Tilling K & Siebert U (2020) Improved two-stage estimation to adjust for treatment switching in randomised trials : g-estimation to address time-dependent confounding. Statistical Methods in Medical Research. View this article in WRRO
• Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB & Karnon J (2020) Adjusting for treatment switching in oncology trials: A systematic review and recommendations for reporting. Value in Health. View this article in WRRO
• Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D & Sowdani A (2019) A review of survival analysis methods used in NICE technology appraisals of cancer treatments: Consistency, limitations and areas for improvement. Medical Decision Making. View this article in WRRO
• Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2019) Assessing the long-term effectiveness of cladribine vs. placebo in the relapsing-remitting multiple sclerosis CLARITY randomized controlled trial and CLARITY Extension using treatment switching adjustment methods. Advances in Therapy. View this article in WRRO
• Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) Statistical methods for adjusting estimates of treatment effectiveness for patient nonadherence in the context of time-to-event outcomes and health technology assessment: A systematic review of methodological papers. Medical Decision Making. View this article in WRRO
• Adler AI, Ting S, Dent R & Latimer N (2019) NICE guidance on dapagliflozin with insulin for type 1 diabetes. The Lancet Diabetes & Endocrinology, 7(10), 750-751. View this article in WRRO
• Palmer R, Dimairo M, Cooper C, Enderby P, Brady M, Bowen A, Latimer N, Julious S, Cross E, Alshreef A , Harrison M et al (2019) Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS) : a multicentre, single-blinded, randomised controlled trial. The Lancet Neurology, 18(9), 821-833. View this article in WRRO
• Thomas SA, Drummond AER, Lincoln NB, Palmer RL, das Nair R, Latimer NR, Hackney GL, Mandefield L, Walters SJ, Hatton RD , Cooper CL et al (2019) Behavioural activation therapy for post-stroke depression : the BEADS feasibility RCT. Health Technology Assessment, 23(47), 1-176. View this article in WRRO
• Latimer NR, White IR, Abrams KR & Siebert U (2019) Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?. Statistical Methods in Medical Research, 28(8), 2475-2493. View this article in WRRO
• Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT & Wong SL (2019) Impact of non-randomised dropout on treatment switching adjustment in the relapsing-remitting multiple sclerosis CLARITY trial and the CLARITY extension study. Value in Health, 22(7), 772-776. View this article in WRRO
• Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N & Briggs A (2019) Estimating lifetime benefits associated with immuno-oncology therapies : challenges and approaches for overall survival extrapolations. PharmacoEconomics, 1-10. View this article in WRRO
• Latimer N, Abrams KR & Siebert U (2019) Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. BMC Medical Research Methodology, 19, 69-69. View this article in WRRO
• Bullement A, Latimer NR & Bell Gorrod H (2018) Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study. Value in Health. View this article in WRRO
• Hernandez-Villafuerte K, Fischer A & Latimer NR (2018) Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology. International Journal of Technology Assessment in Health Care, 34(3), 300-316. View this article in WRRO
• Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N, Charles Victor J & Hoch JS (2018) Developing accessible, pictorial versions of health-related quality of life instruments suitable for economic evaluation: a report of preliminary studies conducted in Canada and the United Kingdom. PharmacoEconomics. View this article in WRRO
• Latimer NR, Abrams KR, Lambert PC, Morden JP & Crowther MJ (2018) Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. Statistical Methods in Medical Research, 27(3), 765-784. View this article in WRRO
• Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
• Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 37(4), 377-390. View this article in WRRO
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2017) Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Statistical Methods in Medical Research, 26(2), 724-751.
• Skaltsa K, Ivanescu C, Naidoo S, Phung D, Holmstrom S & Latimer NR (2017) Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology, 12(1), 111-121. View this article in WRRO
• Henshall C, Latimer NR, Sansom L & Ward RL (2016) Treatment switching in cancer trials: Issues and proposals. International Journal of Technology Assessment in Health Care, 32(3), 167-174. View this article in WRRO
• Latimer NR, Henshall C, Siebert U & Bell H (2016) Treatment Switching: statistical and decision making challenges and approaches. International Journal of Technology Assessment in Health Care, 32(3), 160-166. View this article in WRRO
• Thomas SA, Coates E, das Nair R, Lincoln NB, Cooper C, Palmer R, Walters SJ, Latimer NR, England TJ, Mandefield L , Chater T et al (2016) Behavioural Activation Therapy for Depression after Stroke (BEADS): a study protocol for a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. Pilot and Feasibility Studies, 2(1). View this article in WRRO
• Hatswell AJ, Porter J, Lee D, Hertel N & Latimer NR (2016) The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight. Value in Health. View this article in WRRO
• Latimer NR, Bell H, Abrams KR, Amonkar MM & Casey M (2016) Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Medicine, 5(5), 806-815. View this article in WRRO
• Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Pandite L & Motzer RJ (2016) Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology, 90(3), 119-126. View this article in WRRO
• Naidoo S, Ivanescu C, Skaltsa K, Phung D, Holmstrom S & Latimer N (2015) Adjusting overall Survival Estimates for Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer. Value in Health, 18(3), A195-A195.
• Palmer R, Cooper C, Enderby P, Brady M, Julious S, Bowen A & Latimer N (2015) Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial. Trials, 16(1). View this article in WRRO
• Mukherjee SC, Latimer N, Richards P, Nixon RM & Hall PS (2015) Better Reimbursement Decision-Making Based on Expected Cost-Effectiveness: Using Value of Information Decision Analysis to Improve The Design and Efficacy of A Phase Iii Program for Erlotinib. Value in Health, 18(7), A700-A700.
• Porter J, Latimer N, Lee D & Hatswell AJ (2015) Vial Sizes Of Pharmaceuticals For Infusion – The Potential For Cost Reductions And Reduced Wastage By Optimising Fill Volumes. Value in Health, 18(7), A687-A687.
• Latimer NR, Amonkar MM, Stapelkamp C & Sun P (2015) Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Research, 25(6), 528-536.
• Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C & Swann RS (2015) Adjusting for the Confounding Effects of Treatment Switching—The BREAK‐3 Trial: Dabrafenib Versus Dacarbazine. The Oncologist, 20(7), 798-805.
• Latimer NR (2015) Treatment switching in oncology trials and the acceptability of adjustment methods. Expert Review of Pharmacoeconomics & Outcomes Research, 15(4), 561-564.
• Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N & Hoch JS (2015) Preference-based health-related quality of life in the context of aphasia: a research synthesis. Aphasiology, 29(7), 763-780.
• Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal. PharmacoEconomics, 32(12), 1171-1183. View this article in WRRO
• Angus C, Latimer N, Preston L, Li J & Purshouse R (2014) What are the Implications for Policy Makers? A Systematic Review of the Cost-Effectiveness of Screening and Brief Interventions for Alcohol Misuse in Primary Care. Frontiers in Psychiatry. View this article in WRRO
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2014) Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.. Med Decis Making, 34(3), 387-402.
• Latimer NR (2014) Response to "survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach" by Bagust and Beale.. Med Decis Making, 34(3), 279-282.
• Goyder E, Hind D, Breckon J, Dimairo M, Minton J, Everson-Hock E, Read S, Copeland R, Crank H, Horspool K , Humphreys L et al (2014) A randomised controlled trial and cost-effectiveness evaluation of 'booster' interventions to sustain increases in physical activity in middle-aged adults in deprived urban neighbourhoods.. Health Technol Assess, 18(13), 1-210.
• Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, Bermingham A, Clark TW, Latimer N, Fraser M , Perera N et al (2014) Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds.. Health Technol Assess, 18(36), 1-viii.
• Watkins C, Huang X, Latimer N, Tang Y & Wright EJ (2013) Adjusting overall survival for treatment switches: Commonly used methods and practical application. Pharmaceutical Statistics, 12(6), 348-357.
• Latimer NR, Dixon S & Palmer R (2013) Cost-utility of self-managed computer therapy for people with aphasia.. Int J Technol Assess Health Care, 29(4), 402-409.
• Latimer N, Dixon S, Drahota AK & Severs M (2013) Cost--utility analysis of a shock-absorbing floor intervention to prevent injuries from falls in hospital wards for older people.. Age Ageing, 42(5), 641-645.
• Abrams KR, Latimer N, Amonkar M, Stapelkamp C & Casey M (2013) Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis.. Journal of Clinical Oncology, 31(15_suppl), 9040-9040.
• Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC).. Journal of Clinical Oncology, 31(15_suppl), 636-636.
• Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis.. Journal of Clinical Oncology, 31(15_suppl), 9044-9044.
• Collins M & Latimer N (2013) NICE's end of life decision making scheme: impact on population health.. BMJ, 346, f1363.
• Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, Preston LR & Meier PS (2013) Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.. Alcohol Alcohol, 48(2), 180-188.
• Whitehurst DGT & Latimer NR (2013) Clinical evaluation, economic evaluation, and the role of the control group. Medical Acupuncture, 25(1), 2-4.
• Latimer NR (2013) Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.. Med Decis Making, 33(6), 743-754.
• Latimer NR, Bhanu AC & Whitehurst DGT (2012) Inconsistencies in NICE guidance for acupuncture: Reanalysis and discussion. Acupuncture in Medicine, 30(3), 182-186.
• Palmer R, Enderby P, Cooper C, Latimer N, Julious S, Paterson G, Dimairo M, Dixon S, Mortley J, Hilton R , Delaney A et al (2012) Computer therapy compared with usual care for people with long-standing aphasia poststroke: a pilot randomized controlled trial.. Stroke, 43(7), 1904-1911.
• Mulhern B, Rowen D, Jacoby A, Marson T, Snape D, Hughes D, Latimer N, Baker GA & Brazier JE (2012) The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy and Behavior, 24(1), 36-43.
• Morden JP, Lambert PC, Latimer N, Abrams KR & Wailoo AJ (2011) Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.. BMC Med Res Methodol, 11, 4. View this article in WRRO
• Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J & Conaghan PG (2011) Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.. Pharmacoeconomics, 29(3), 225-237.
• Latimer N (2009) NICE guideline on osteoarthritis: is it fair to acupuncture? Yes.. Acupunct Med, 27(2), 72-75.
• Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG & National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group (2009) Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.. BMJ, 339, b2538.
• Barham L, Lewis D & Latimer N (2007) One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations.. Sex Transm Infect, 83(6), 441-446.
• Alshreef A, Latimer N, Tappenden P & Dixon S () Assessing Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Simulation Study. Medical Decision Making.
• Latimer NR, Taylor K, Hatswell AJ, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D () An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?. PharmacoEconomics.
• Latimer NR & Rutherford MJ () Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know. PharmacoEconomics.
• Lally P, Kennedy F, Smith S, Beeken R, Buck C, Thomas C, Counsell N, Wyld L, Martin C, Williams S , Roberts A et al () The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate, and colorectal cancer in the UK. Cancer Medicine. View this article in WRRO
• Chang JY, Chilcott JB & Latimer N () Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments. PharmacoEconomics.
• Latimer NR, Dewdney A & Campioni M () A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study. BMC Medical Research Methodology, 24(1).
• Swaby L, Perry DC, Walker K, Hind D, Mills A, Jayasuriya R, Totton N, Desoysa L, Chatters R, Young B , Sherratt F et al () Bracing Adolescent Idiopathic Scoliosis (BASIS) study – night-time versus full-time bracing in adolescent idiopathic scoliosis: study protocol for a multicentre, randomized controlled trial. Bone & Joint Open, 4(11), 873-880.
• Broomfield J, Abrams KR, Freeman S, Latimer N, Rutherford MJ & Crowther MJ () Modeling the multi‐state natural history of rare diseases with heterogeneous individual patient data: A simulation study. Statistics in Medicine.
• Sweeting MJ, Rutherford MJ, Jackson D, Lee S, Latimer NR, Hettle R & Lambert PC () Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial. Medical Decision Making.
• Latimer NR, Bhadhuri A, Alshreef AO, Palmer R, Cross E, Dimairo M, Julious S, Cooper C, Enderby P, Brady MC , Bowen A et al () Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation. Clinical Rehabilitation, 026921552097534-026921552097534.
• Goyder EC, Maheswaran R & Read S () Associations between neighbourhood environmental factors and the uptake and effectiveness of a brief intervention to increase physical activity. Journal of Public Health. View this article in WRRO
• Tai T-A, Latimer N, Benedict A, Kiss Z & Nikolaou A () Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to NICE and Impact on Decision-Making. Value in Health.
• Gray J, Sullivan T, Latimer N, Salter A, Sorich M, Ward R & Karnon J () Extrapolation of survival curves using standard parametric models and flexible parametric spline models: comparisons in large registry cohorts with advanced cancer. Medical Decision Making.
• Latimer N, Pollard D, Towse A, Henshall C, Sansom L, Ward R, Bruce A & Deakin C () Challenges in valuing and paying for combination regimens in oncology: Reporting the perspectives of a multi-stakeholder, international workshop. BMC Health Services Research.

Conference proceedings papers

• Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) TESTING A SURVIVAL EXTRAPOLATION ALGORITHM FOR CANCER IMMUNOTHERAPIES: PASS OR FAIL?. VALUE IN HEALTH, Vol. 26(12) (pp S13-S13)
• Franklin M, Porter A, de Vocht F, Kearns B, Latimer N, Hernandez M, Young T & Kidger J (2023) COMBINING CAUSAL INFERENCE AND WITHIN-TRIAL ECONOMIC EVALUATION METHODS TO ASSESS THE COST-EFFECTIVENESS OF A MENTAL HEALTH SERVICE USING REAL-WORLD DATA: THE QUASI-EXPERIMENTAL ADAPT STUDY. VALUE IN HEALTH, Vol. 26(12) (pp S87-S87)
• Gorrod BH, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) ADJUSTING FOR SWITCHES TO MULTIPLE TREATMENTS IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF INVERSE PROBABILITY WEIGHTING AND TWO-STAGE ESTIMATION METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S394-S394)
• Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) EVALUATING BIAS ASSOCIATED WITH INADEQUATE VARIABLE SELECTION WHEN USING INVERSE PROBABILITY OF CENSORING WEIGHTS TO ADJUST FOR TREATMENT SWITCHES IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(12) (pp S423-S424)
• Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) ACCOUNTING FOR STUDY HETEROGENEITY WHEN MODELLING THE MULTI-STATE NATURAL HISTORY OF RARE DISEASES. VALUE IN HEALTH, Vol. 26(12) (pp S421-S422)
• Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) RWD66 Application of the target trial framework for estimating comparative effectiveness using real-world data-a systematic review. Value in Health, Vol. 25(12 Suppl) (pp S461-S461). Vienna, Austria, 6 November 2022 - 9 November 2022.
• Kennedy F, Miller N, Roberts A, Beeken RJ, Greenfield D, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) Promoting physical activity via a smartphone application in people living with breast, prostate or colorectal cancer: study protocol for a randomised pilot trial (APPROACH). PSYCHO-ONCOLOGY, Vol. 31 (pp 20-20)
• Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529)
• Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520)
• Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) Application of the Target Trial Framework for Estimating Comparative Effectiveness Using Real-World Data - A Systematic Review. VALUE IN HEALTH, Vol. 25(12) (pp S461-S461)
• Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616)
• Amy J-YC, Latimer NR, Gillespie D & Chilcott J (2020) PREVALENCE, CHARACTERISTICS AND KEY ISSUES OF MODELLING TREATMENT SEQUENCES IN HEALTH ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW OF NICE TECHNOLOGY APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S606-S606)
• Latimer N, White I, Tilling K & Siebert U (2020) ESTIMATING THE TRUE VALUE OF NEW ONCOLOGY TREATMENTS: IMPROVED TWO-STAGE ESTIMATION TO ADJUST FOR TREATMENT SWITCHING IN RANDOMISED TRIALS. MEDICAL DECISION MAKING, Vol. 40(1) (pp E294-E295)
• Tai TA, Latimer NR, Benedict Á, Kiss Z & Nikolaou A (2019) PCN150 IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING. Value in Health, Vol. 22 (pp S464-S464)
• Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) FC060THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS. Nephrology Dialysis Transplantation, Vol. 34(Supplement_1)
• Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 34
• Tai TA, Latimer NR, Benedict A, Kiss Z & Nikolaou A (2019) IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING. VALUE IN HEALTH, Vol. 22 (pp S464-S464)
• O'Brien S, Cork L, Bandeira V, Bescoby R, Foroni L, Alaily L, Osborne W, Bell-Gorrod H, Latimer N, Apperley J , Hedgley C et al (2018) Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. Blood, Vol. 132(Supplement 1) (pp 457-457)
• Muresan B, Mamolo CM, Cappelleri JC, Mokgokong R, Palaka A, Hills RK, Latimer N & Heeg B (2018) Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, Vol. 132(Supplement 1) (pp 2712-2712)
• Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
• Latimer NR (2018) PCN317 - THE CANCER DRUGS FUND: KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SET. Value in Health, Vol. 21 (pp S68-S68)
• Thomas SA, Drummond A, Lincoln NB, Palmer R, dasnair R, Latimer N, Hackney G, Hatton R, Walters S, Mandefield L , Cooper C et al (2017) Behavioural activation therapy for depression after stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. INTERNATIONAL JOURNAL OF STROKE, Vol. 12 (pp 15-15)
• Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) Impact Of Non-Randomised Drop-Out On Treatment Switching Adjustment In The Relapsing-Remitting Multiple Sclerosis Clarity Trial And The Clarity Extension Study. Value in Health, Vol. 20(9) (pp A769-A769)
• Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) Adjusting for Treatment Switching in the Relapsing-Remitting Multiple Sclerosis Clarity Trial and the Clarity Extension Study. Value in Health, Vol. 20(9) (pp A718-A718)
• Latimer N & Abrams KR (2017) TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 20(5) (pp A314-A314) View this article in WRRO
• Gorrod BH, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) ADJUSTING FOR TREATMENT SWITCHING IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY. VALUE IN HEALTH, Vol. 20(9) (pp A718-A718)
• Watkins CL, Latimer N, Wang J & Wright EJ (2016) Guidance On Selecting Appropriate Methods When Considering Adjusting Overall Survival For Treatment Switch In Oncology Studies. Value in Health, Vol. 19(7) (pp A398-A398)
• Bell H, Latimer N, Amonkar M & Swann S (2015) Adjusting For Treatment Switching in Rcts – Identifying, Analysing and Justifying Appropriate Methods: a Case Study in Metastatic Melanoma. Value in Health, Vol. 18(7) (pp A338-A338)
• Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Bartlett-Pandite AN & Motzer R (2015) Crossover in oncology clinical trials.. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e15592-e15592)
• Bell H, Latimer N, Amonkar M & Casey M (2014) Adjusting for Treatment Crossover in A Trametinib Metastatic Melanoma Rct: Identifying the Appropriate Method. Value in Health, Vol. 17(7) (pp A577-A577)
• Latimer N, Amonkar M, Stapelkamp C & Sun P (2014) Abstract CT330: Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib inBRAFV600+ metastatic melanoma. Clinical Trials
• Boucher R, Abrams KR, Crowther MJ, Lambert PC, Wailoo AJ & Latimer NR (2013) ADJUSTING FOR TREATMENT SWITCHING IN CLINICAL TRIALS WHEN ONLY SUMMARY DATA ARE AVAILABLE - AN EVALUATION OF POTENTIAL METHODS. VALUE IN HEALTH, Vol. 16(7) (pp A610-A611)
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2013) A GUIDE TO ADJUSTING SURVIVAL TIME ESTIMATES TO ACCOUNT FOR TREATMENT SWITCHING IN RANDOMISED CONTROLLED TRIALS. VALUE IN HEALTH, Vol. 16(7) (pp A325-A325)
• Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Abrams KR, Latimer N, Amonkar M, Stapelkamp C, Casey M & Grp T (2013) Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Latimer N, Lambert P, Crowther M, Abrams KR, Wailoo AJ & Morden JP (2012) METHODS FOR ESTIMATING SURVIVAL BENEFITS IN THE PRESENCE OF TREATMENT CROSSOVER: A SIMULATION STUDY. VALUE IN HEALTH, Vol. 15(7) (pp A462-A462)
• Latimer N (2011) METHODS FOR EXTRAPOLATING SURVIVAL DATA USED IN NICE TECHNOLOGY APPRAISALS: INCONSISTENCIES AND LIMITATIONS. VALUE IN HEALTH, Vol. 14(7) (pp A242-A242)
• Rowen D, Mulhern B, Brazier J, Jacoby A, Marson T, Latimer N, Snape D, Baker G & Hughes D (2010) Using the Liverpool Quality of Life battery to develop a health state classification system for Epilepsy. QUALITY OF LIFE RESEARCH, Vol. 19 (pp 57-57)
• Gyldmark M, Gatzemeier U, Nicolson M, Latimer N & Walzer S (2008) EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM. VALUE HEALTH, Vol. 11(6) (pp A357-A357)
• Ducournau P, Latimer N, Sabate E & Walzer S (2008) EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE. VALUE HEALTH, Vol. 11(6) (pp A471-A472)
• Latimer N & Lewis G (2008) The cost of adults with severe active rheumatoid arthritis who do not respond to treatment following treatment with one TNF inhibitor. RHEUMATOLOGY, Vol. 47 (pp II123-II124)
• Somerville M, Scott D, Hancock M, Geary U & Latimer N (2008) The impact of rituximab on resource use in a UKNHS rheumatology day care service. RHEUMATOLOGY, Vol. 47 (pp II119-II120)
• Latimer N & Lewis G (2008) What are the costs of treating severe active rheumatoid arthritis with TNF inhibitors, rituximab and abatacept?. RHEUMATOLOGY, Vol. 47 (pp II122-II123)
• Latimer NR & Lewis GJ (2005) A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK. VALUE HEALTH, Vol. 8(6) (pp A58-A58)

Reports

• Chang J-YA, Chilcott JB & Latimer NR (2024) Leveraging real-world data to assess treatment sequences in health economic evaluations: a study protocol for emulating target trials using the English Cancer Registry and US Electronic Health Records-Derived Database View this article in WRRO
• Latimer N & Pollard D (2019) Pre-read document 1: Challenges in valuing and paying for combination regimens in oncology View this article in WRRO
• Latimer NR, White IR, Abrams KR & Sieburt U (2017) Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times? View this article in WRRO
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ & Morden JP (2014) Assessing methods for dealing with treatment crossover in clinical trials: A follow-up simulation study View this article in WRRO

Scholarly editions

• Mulhern B, Rowen D, Brazier J, Jacoby A, Marson T, Snape D, Hughes D, Latimer N & Baker GA (2010) Developing a health state classification system from NEWQOL for epilepsy using classical psychometric techniques and Rasch analysis: a technical report.

Posters

• Bell H, Latimer N, Amonkar M & Casey M Adjusting for treatment crossover in a trametinib metastatic melanoma RCT: Identifying the appropriate method.

Other

• Palmer R, Cooper C, Enderby P, Brady M, Julious S, Bowen A, Latimer N, Gossage-Worrall R, Cross E & Harrison M (2018) Big CACTUS study protocol v5.0 31may17.

Preprints

• Franklin M, Porter A, De Vocht F, Kearns B, Latimer N, Alava MH, Young T & Kidger J (2023) Combining causal inference and within-trial economic evaluation methods to assess comparative cost-effectiveness using real-world data: a tutorial with recommendations based on the quasi-experimental ADAPT study of a redesigned mental health service.
• Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al () An App With Brief Behavioural Support to Promote Physical Activity After a Cancer Diagnosis (APPROACH): Study Protocol for a Pilot Randomised Controlled Trial, Research Square Platform LLC.